Document is current

Article History

Received: 15 March 2024

Accepted: 31 October 2024

First Online: 26 November 2024

Declarations

:

: The data in this study were collected during routine care and retrieved retrospectively, which was approved by the Medical Ethical Committee (METc) of the VUmc Medical Center and at the local clinics in the PredictND study. All patients provided written informed consent for their data to be used for research purposes.

: Not applicable.

: HR performed contract research for Combinostics; all funding is paid to her institution. JL is a shareholder at Combinostics and Combinostics holds three patents regarding its DSI technology. Research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU-JPND, EU-IHI, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, Eisai, Combinostics. WF holds the Pasman chair. WF is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). WF has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, European Brain Council. WF is consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, and Eisai. WF is member of steering cie of NovoNordisk evoke/evoke+. WF participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. WF is member of the steering committee of EVOKE/EVOKE+ (NovoNordisk). All funding is paid to her institution. WF is member of the steering committee of PAVE, and Think Brain Health. WF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF is associate editor at Brain. FB is steering committee or Data Safety Monitoring Board member for Biogen, Merck, Eisai and Prothena. FB is advisory board member for Combinostics, Scottish Brain Sciences. Consultant for Roche, Celltrion, Rewind Therapeutics, Merck, Bracco. FB has research agreements with ADDI, Merck, Biogen, GE Healthcare, Roche. FB is co-founder and shareholder of Queen Square Analytics LTD. All other authors report no financial disclosures or conflicts of interest.